Skip to main content
. 2022 Aug 5;2022:4782361. doi: 10.1155/2022/4782361

Figure 4.

Figure 4

SBF2-AS1 represses the survival of VSMCs and HASMCs by targeting miR-520f-3p/SMARCD1 axis in vitro. (a–d) The VSMCs and HASMCs were treated with exosomes derived from BMSCs transfected with SBF2-AS1 shRNA or cotreated with SMARCD1 overexpressing plasmid or miR-520f-3p inhibitor. (c and d) The caspase-3 activity was analyzed by the caspase-3 Activity Assay Kit. All experiments were performed in triplicate. ∗∗ indicated P < 0.01.